U.S. Markets open in 2 hrs 47 mins

Kenneth Harris reports 13.94% stake in Cesca Therapeutics

On February 18, the company consummated an Agreement and Plan of Merger, by and among ThermoGenesis Corp., TotipotentRX Corporation, Mitchel Sivilotti and Kenneth L. Harris, dated as of July 15, 2013. As part of the Merger Agreement, TotipotentRX had the right to select two nominees to Cesca's board of directors of which Kenneth L. Harris was appointed effective as of the closing date. Because as of the closing date TotipotentRX had not yet selected its second nominee, TotipotentRX assigned this selection right to the former directors of TotipotentRX, including Harris, provided such selection occurs prior to June 30, 2014.